Previous 10 | Next 10 |
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results Plan to Meet with Regulatory Authorities to Determi...
Shares of Anavex Life Sciences (NASDAQ: AVXL) , a clinical-stage biotech that specializes in therapies to treat neurodegenerative and neurodevelopmental diseases, fell by 23.5% on Monday. The stock closed on Friday at $11.89. After opening higher at $12.46 Monday, it rose to $12.49 ...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing di...
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
Summary Anavex will present results from its phase 2b/3 trial for blarcamesine for Alzheimer's disease at the CTAD conference in San Francisco on December 1st. A past trial suggests that Anavex's blarcamesine modifies mild Alzheimer's disease in some patients at 148 weeks. At ...
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Anavex Life Sciences' ( NASDAQ: AVXL ) ANAVEX2-73 (blarcamesine) to treat Fragile X syndrome (FXS). FXS is a genetic disorder that causes developmental delays, learning disabilities and...
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which is estimated to increase to around 13.8 million by 2060. W...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders i...
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
LOS ANGELES, April 23, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...